EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety

Hans Johnson iD, Ashley Kieran Clift, Daniel Reisel, David R Huang

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hans Johnson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digital Health and Care, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Weight Reduction Programs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We evaluated the weight loss efficacy and safety of a national digital weight loss service (DWLS) and explored associations between digital engagement and outcomes in adults prescribed dual GIP/GLP‐1RA and GLP‐1RA. Materials and Methods We conducted a retrospective longitudinal cohort analysis of adults prescribed dual GIP/GLP‐1RA and GLP‐1RA between August 2024 and July 2025 within the Voy DWLS in the United Kingdom (UK). Digitally engaged patients met all three criteria: (i) ≥1 coaching session; (ii) weekly weight logging (≥4/month); and (iii) ≥1 additional in‐app interaction. Weight‐loss trajectories were modelled using mixed models for repeated measures (MMRM). Kaplan–Meier methods and Cox models examined time to attain weight loss thresholds (≥5, ≥10, ≥15, ≥20, ≥25%). Safety events were summarised as rates per 1000 patient‐months with 95% CIs.

Results

The cohort included 106 653 adults (mean age 42.3 ± 12.7 years; 77.9% female; baseline BMI 35.2 ± 6.2 kg/m 2 ). Whilst 79.7% ( n = 84 955) used the digital application, 5.7% ( n = 6086) met maximal engagement, with 100 567 classed as not engaged. Across 11 months, engaged patients achieved greater adjusted weight loss than not engaged (21.5% [95% CI −22.0 to −21.1] vs. 17.0% [−17.2 to −16.8]; absolute difference 4.5 percentage points; p < 0.001). Kaplan–Meier analyses showed consistently higher likelihood of milestone attainment for engaged participants (≥5%: HR 1.42, 95% CI 1.38–1.46; ≥10%: HR 1.46, 1.41–1.52; ≥15%: HR 1.53, 1.45–1.61; ≥20%: HR 1.62, 1.50–1.75; ≥25%: HR 1.86, 1.64–2.10; all p < 0.001). Safety analyses over 290 050 patient‐months showed incidence 1.57 per 1000 patient‐months, with no excess risk in engaged groups (IRR 0.83, 95% CI 0.60–1.15).

Conclusions

Digital engagement was associated with 4.5 percentage points greater weight loss (21.5% vs. 17.0%), faster milestone achievement, and comparable safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossGlucagon-Like Peptide-1 Receptor AgonistsObesityWeight Reduction ProgramsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeLongitudinal StudiesUnited KingdomTelemedicine

Stichwörter der Autor:innen

GIP/GLP‐1 RAGLP‐1 RAdigital healthobesityretrospective studysafetytherapyweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Digital Health and Care, University of Bristol, Bristol, UK.
  • Department of Education, University of Oxford, Oxford, UK.
  • Department of Clinical Research, Voy, Menwell Ltd, London, UK.
  • Department of Surgery & Cancer, Imperial College London, London, UK.
  • EGA Institute for Women's Health, University College London, London, UK.

ORCID-Profile: Hans Johnson

Zitieren

APA

Johnson, H., Clift, A. K., Reisel, D., & Huang, D. R. (2026). Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70244

Vancouver

Johnson H, Clift AK, Reisel D, Huang DR. Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70244

BibTeX
@article{Johnson2026,
  author = {Johnson, Hans and Clift, Ashley Kieran and Reisel, Daniel and Huang, David R},
  title = {Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70244}
}
Kostenlos starten →